FAKTOR OPTIONSSCHEIN - ELI LILLY & CO | Delayed Deutsche Boerse AG 11:50:35 03/07/2024 BST | ||
| 277.2 EUR | +0.88% |
|
| Current month | -0.66% | ||
| 1 month | +22.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 277.2 | +0.88% |
| 02/07/24 | 274.7 | -1.93% |
| 01/07/24 | 280.2 | +1.29% |
| 28/06/24 | 276.6 | +0.18% |
| 27/06/24 | 276.1 | +1.01% |
Delayed Quote Deutsche Boerse AG
Last update July 03, 2024 at 11:50 am
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PN2LLY |
| ISIN | DE000PN2LLY5 |
| Date issued | 09/11/2021 |
| Strike | 905.4 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 30 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 281.3 € |
|---|---|
| Lowest since issue | 23.51 € |
| Spread | 1.24 € |
| Spread % | 0.45% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
906.7
USD
Average target price
870.3
USD
Spread / Average Target
-4.02%
- Stock Market
- Certificates
- Certificat
